Article
Clinical Neurology
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Carlo Lovati, Davide Bertuzzo, Florindo D'Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Francesca Schiano Di Cola, Angelo Ranieri, Bruno Colombo, Francesco Bono, Maria Albanese, Sabina Cevoli, Piero Barbanti
Summary: This study found that in patients with chronic migraine, unilateral pain, a good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Andrew M. Strassman, Agustin Melo-Carrillo, Timothy T. Houle, Aubrey Adams, Mitchell F. Brin, Rami Burstein
Summary: This study investigated the mechanism of action of Atogepant on activation of mechanosensitive C- and A delta-meningeal nociceptors following cortical spreading depression. The results showed that Atogepant significantly reduced the response amplitude and probability of response in both C- and A delta-fibers at different time intervals.
Article
Clinical Neurology
Simone Quintana, Marco Russo, Gian Camillo Manzoni, Paola Torelli
Summary: This observational study compares the efficacy, safety, and impact of anti-CGRP monoclonal antibodies on additional parameters such as disability in social, family, and work activities.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, Cinzia Aurilia, Gabriella Egeo, Carlo Lovati, Valentina Favoni, Armando Perrotta, Ilaria Maestrini, Renata Rao, Luigi d'Onofrio, Cinzia Finocchi, Marco Aguggia, Francesco Bono, Angelo Ranieri, Maria Albanese, Vittorio Di Piero, Sabina Cevoli, Claudia Altamura, Piero Barbanti
Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Saval Khanal, Martin Underwood, Seyran Naghdi, Anna Brown, Callum Duncan, Manjit Matharu, Hema Mistry
Summary: This study conducted an economic evaluation of pharmacological treatments for chronic migraine in adults and found that both Botox and Erenumab are cost-effective options. Although Erenumab had more incremental economic benefits compared to Botox, its cost-effectiveness ratios were above the most common willingness-to-pay thresholds.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, Luigi Francesco Iannone, Carlo Baraldi, Renata Rao, Francesca Schiano di Cola, Raffaele Ornello, Sabina Cevoli, Carlo Lovati, Maria Albanese, Armando Perrotta, Ilaria Cetta, Sergio Soeren Rossi, Valentina Taranta, Massimo Filippi, Pierangelo Geppetti, Simona Sacco, Claudia Altamura
Summary: This study evaluated the outcome of migraine patients treated with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr). The effectiveness of these mAbs did not differ between the first and second year of treatment. The results suggest that anti-CGRP/CGRPr mAbs are effective in both years.
JOURNAL OF NEUROLOGY
(2023)
Review
Medicine, General & Internal
Lars Edvinsson
Summary: Migraine is a common neurovascular disorder, affecting over 15% of the global population. Women are three times more likely to suffer from migraine compared to men. The underlying mechanisms of migraine are still largely unknown, but molecules such as CGRP play a crucial role in its pathophysiology.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Clinical Neurology
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Summary: This study analyzed the long-term sustained effectiveness of erenumab in treating resistant chronic migraine. The findings revealed that only a minority of patients maintained good efficacy over a period of two years. However, erenumab can still provide relief in terms of reducing migraine load and related disability in some patients.
JOURNAL OF HEADACHE AND PAIN
(2022)
Review
Clinical Neurology
Simona Guerzoni, Carlo Baraldi, Luca Pani
Summary: Chronic migraine is a challenge for physicians, and despite the introduction of monoclonal antibodies targeting CGRP, some patients still do not experience complete relief. The combination of onabotulinumtoxinA and anti-CGRP mAbs may offer a reliable option for these patients. However, there is limited evidence and regulatory restrictions regarding this combination therapy, calling for further well-designed studies and pharmacoeconomic analysis.
NEUROLOGICAL SCIENCES
(2022)
Review
Clinical Neurology
Davide Mascarella, Eleonora Matteo, Valentina Favoni, Sabina Cevoli
Summary: Anti-CGRP monoclonal antibodies have shown remarkable efficacy and safety in the treatment of migraines. Real-world studies have provided additional insights beyond clinical trials, confirming the effectiveness of these revolutionary medications.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Simone de Vries Lentsch, Ingrid M. Garrelds, A. H. Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink
Summary: This study evaluated the serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab, and examined their association with clinical treatment response. The results showed that lower levels of serum CGRP-LI 2-4 weeks after starting treatment with erenumab were associated with a higher reduction in migraine days after three months of treatment. This suggests that changes in CGRP levels shortly after starting erenumab are important for its clinical effect.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Food Science & Technology
Andreas A. A. Argyriou, Emmanouil V. V. Dermitzakis, Georgia Xiromerisiou, Michail Vikelis
Summary: This study aimed to evaluate the effectiveness of combining dual therapy with BTX and anti-CGRP MAbs in treatment-refractory CM patients. Retrospective review of medical files of 19 patients showed that dual therapy was effective and associated with significant clinical improvement in the majority of cases, with favorable safety and tolerability.
Article
Clinical Neurology
Marcella Curone, Vincenzo Tullo, Henri Albert Didier, Gennaro Bussone
Summary: Monoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with medication overuse headache.
NEUROLOGICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Bianca Raffaelli, Maria Terhart, Mira Pauline Fitzek, Kristin Sophie Lange, Jasper Mecklenburg, Lucas Hendrik Overeem, Anke Siebert, Elisabeth Storch, Uwe Reuter
Summary: Discontinuation of treatment with CGRP(-receptor) monoclonal antibodies (mAb) does not affect free CGRP plasma concentrations, but leads to a significant decrease in total CGRP concentrations after three months. This study highlights the importance of understanding the mechanisms behind the increase in migraine frequency following mAb discontinuation.
Article
Clinical Neurology
Austeja Dapkute, Jurgita Vainauskiene, Kristina Ryliskiene
Summary: Despite new therapies, migraine remains undertreated. This study investigates patients' experiences and preferences with erenumab for high frequency episodic and chronic migraine in Lithuania. Results showed that the majority of respondents found erenumab effective and experienced improvement within the first month. Erenumab significantly reduced migraine headache days and frequency, but some patients experienced wearing-off effects during treatment and migraine rebound after discontinuation. Constipation was the most common adverse event. Further research is needed to explore post-cessation deterioration of treatment effect.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Daniele Martinelli, Sebastiano Arceri, Roberto De Icco, Marta Allena, Elena Guaschino, Natascia Ghiotto, Vito Bitetto, Gloria Castellazzi, Giuseppe Cosentino, Grazia Sances, Cristina Tassorelli
Summary: Onabotulinum toxin-A showed significant efficacy in preventing high-frequency episodic migraine, reducing monthly migraine days, headache days, and intake of acute medications, as well as improving disability and quality of life for patients.
Article
Clinical Neurology
Sara Bottiroli, Federica Galli, Elena Ballante, Stefania Pazzi, Grazia Sances, Elena Guaschino, Marta Allena, Cristina Tassorelli
Summary: This study tested the validity of the Severity of Dependence Scale in detecting dependence behaviors in patients with chronic migraine and medication overuse, finding that the scale was effective in predicting substance dependence and could serve as an interesting screening tool for identifying dependency-like behaviors in these patients.
Article
Clinical Neurology
Marta Matamala-Gomez, Sara Bottiroli, Grazia Sances, Marta Allena, Roberto De Icco, Natascia Ghiotto, Elena Guaschino, Giorgio Sandrini, Cristina Tassorelli
Summary: This study investigates the influence of different visual feedback conditions on pain perception in patients with chronic migraine, and evaluates the impact of emotional face expressions on visual analgesia. The observation of positive emotional face resulted in modulation of pain perception, possibly through the mediation of emotion regulation. These findings suggest the potential use of visual induced analgesia as a cognitive behavioral intervention to control pain perception in chronic migraine patients.
Article
Clinical Neurology
Fabrizio Stasolla, Alessandro O. Caffo, Sara Bottiroli, Donatella Ciarmoli
Summary: The study found that an Assistive Technology setup can help improve the performance and positive participation of adolescents recovering from a minimally conscious state. Social raters gave positive scores to the use of this technology.
DEVELOPMENTAL NEUROREHABILITATION
(2022)
Review
Clinical Neurology
D. Martinelli, M. M. Pocora, R. De Icco, A. Putorti, Cristina Tassorelli
Summary: This review discusses the recent findings on the epidemiology and pathophysiology of migraine triggers, highlighting the need for multiple triggers to induce an attack and the importance of identifying the true triggers for effective migraine management.
CURRENT OPINION IN NEUROLOGY
(2022)
Article
Clinical Neurology
Ettore Beghi, Elisabetta Pupillo, Elisa Bianchi, Valentina Bonetto, Silvia Luotti, Laura Pasetto, Caterina Bendotti, Massimo Tortarolo, Francesca Sironi, Laura Camporeale, Alexander V. Sherman, Sabrina Paganoni, Ada Scognamiglio, Fabiola De Marchi, Paolo Bongioanni, Renata Del Carratore, Claudia Caponnetto, Luca Diamanti, Daniele Martinelli, Andrea Calvo, Massimiliano Filosto, Alessandro Padovani, Stefano Cotti Piccinelli, Claudia Ricci, Stefania Dalla Giacoma, Nicoletta De Angelis, Maurizio Inghilleri, Rossella Spataro, Vincenzo La Bella, Giancarlo Logroscino, Christian Lunetta, Claudia Tarlarini, Jessica Mandrioli, Ilaria Martinelli, Cecilia Simonini, Elisabetta Zucchi, Maria Rosaria Monsurro, Dario Ricciardi, Francesca Trojsi, Nilo Riva, Massimo Filippi, Isabella Laura Simone, Gianni Soraru, Cristina Spera, Lucia Florio, Sonia Messina, Massimo Russo, Gabriele Siciliano, Amelia Conte, Maria Valeria Saddi, Nicola Carboni, Letizia Mazzini
Summary: This study is a clinical trial on the effects of RNS60 in ALS patients. The results indicate that RNS60 has positive effects on respiratory and bulbar function, suggesting further investigation is warranted.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Psychiatry
Ada Ghiggia, Sara Bottiroli, Vittorio Lingiardi, Cristina Tassorelli, Federica Galli, Lorys Castelli
Summary: This study aimed to investigate the prevalence and association between alexithymia and psychological distress in individuals with fibromyalgia (FM) and chronic migraine (CM). The results showed significantly higher scores for alexithymia and psychological distress in FM compared with CM and healthy controls. Additionally, the degree of alexithymia had a significantly higher influence on psychological distress in the patient groups.
JOURNAL OF PSYCHOSOMATIC RESEARCH
(2022)
Article
Clinical Neurology
Lucas Hendrik Overeem, Raffaele Ornello, Maria Magdalena Pocora, Uwe Reuter, Simona Sacco, Cristina Tassorelli, Aud Nome Dueland, Bianca Raffaelli, Daniele Martinelli
Summary: In patients with chronic migraine treated with BoNTA, the use of concomitant oral preventive treatment is common and generally safe, but may lead to a smaller reduction in monthly headache days compared to patients without concomitant treatment.
Review
Biochemistry & Molecular Biology
Chiara Demartini, Miriam Francavilla, Anna Maria Zanaboni, Sara Facchetti, Roberto De Icco, Daniele Martinelli, Marta Allena, Rosaria Greco, Cristina Tassorelli
Summary: In recent years, efforts have been made to identify reliable biomarkers for migraine diagnosis and treatment response. This review summarizes the alleged diagnostic and therapeutic migraine biomarkers found in biofluids and discusses their role in the disease's pathogenesis. The potential issues affecting biomarker analysis, such as bias and confounding data, are also discussed. CGRP and other factors associated with the trigeminovascular system may offer precision medicine opportunities, but factors like sample stability and confounding factors should be considered.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Food Science & Technology
Daniele Martinelli, Maria Magdalena Pocora, Roberto De Icco, Marta Allena, Gloria Vaghi, Grazia Sances, Gloria Castellazzi, Cristina Tassorelli
Summary: This study used machine learning algorithms to predict treatment response to OnabotulinumtoxinA (BonT-A) in patients with migraine. The results showed that none of the clinical characteristics could distinguish responders from nonresponders in the chronic migraine group, while a pattern of four features (age at onset of migraine, opioid use, anxiety subscore, and Migraine Disability Assessment score) correctly predicted response in high-frequency episodic migraine.
Review
Clinical Neurology
Sara Bottiroli, Alessia Renzi, Elena Ballante, Roberto De Icco, Grazia Sances, Annalisa Tanzilli, Tomaso Vecchi, Cristina Tassorelli, Federica Galli
Summary: The study aims to explore the personality traits associated with chronic headaches through a systematic review and quantitative meta-analysis. The results show that chronic headache patients scored higher on Hypochondriasis and Hysteria Scales compared to healthy controls. The systematic review also reveals higher levels of depressive and anxious personality dimensions and pain catastrophizing in chronic headache patients. Identifying the key personality traits involved in headache disorders is crucial for developing psychological interventions.
PAIN RESEARCH & MANAGEMENT
(2023)
Meeting Abstract
Clinical Neurology
Sara Bottiroli, Rosaria Greco, Annamaria Zanaboni, Marta Allena, Elena Guaschino, Natascia Ghiotto, Roberto De Icco, Grazia Sances, Cristina Tassorelli
Meeting Abstract
Clinical Neurology
Lara Ahmad, Marta Allena, Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni, Sara Bottiroli, Federica Tanganelli, Daniele Martinelli, Alessia Putorti, Grazia Sances, Roberto De Icco, Cristina Tassorelli
Article
Geriatrics & Gerontology
Claudia Rodella, Sara Bernini, Silvia Panzarasa, Elena Sinforiani, Marta Picascia, Silvana Quaglini, Elena Cavallini, Tomaso Vecchi, Cristina Tassorelli, Sara Bottiroli
Summary: The study evaluated the effectiveness of a combined treatment protocol involving computerized cognitive training and anodal transcranial direct current stimulation in patients with early cognitive impairment. Results showed improvements in working memory and attention/processing speed in the treatment group compared to the control group, with the treatment group maintaining stability at 6 months. Age, mood, and baseline scores were found to play a role in predicting treatment effects.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)